Take Action
Respond to the CDC RFI on strengthening public health data exchange
The Centers for Disease Control and Prevention (CDC) has issued a Request for Information (RFI; CDC-2026-1519) seeking input on how data intermediaries can improve the secure, efficient, and standardized exchange of health data between health care organizations and public health agencies. Data intermediaries include health information exchanges, health data utilities, and other data-sharing networks, and are responsible for connecting health care providers, laboratories, public health agencies, and other data sources. CDC seeks input specifically on technical capabilities and standards, sustainable funding models, governance and accountability, privacy protections, and approaches to reducing the administrative and technical burden of data exchange. Comments will aid CDC in advancing broader goals to prevent disease, detect emerging threats, drive state-of-the-art solutions that empower communities, and strengthen public health systems for a safer, healthier nation.
Action opportunity: Public health organizations, health care providers, research institutions, data organizations, and other interested parties are encouraged to respond on the docket by the November 20 deadline.
Nominate qualified experts and consumer representatives to FDA advisory committees
The U.S. Food and Drug Administration (FDA) is seeking nominations from scientists, clinicians, researchers, technical professionals, patient advocates, and consumer representatives to broaden the expertise and perspectives informing its advisory committees. These committees bring together scientific experts along with patient advocates and consumer representatives to evaluate the evidence on drugs, vaccines, biologics, medical devices, and other FDA-regulated products — providing independent recommendations that help the FDA make well-informed decisions on behalf of the U.S. public.
Self-nominations for committee membership are welcome, and members may serve terms of up to four years. Organizations and individuals with relevant scientific expertise or community and consumer experience are encouraged to apply.
Action opportunity: Interested parties are encouraged to submit nominations for FDA advisory committees via the centralized application portal by the respective deadlines. Consumer representative nominations must be submitted by November 15 while nominations for scientific, technical, professional, and other voting members must be submitted by November 30.
Respond to the NIH RFI on reducing administrative burden in federally funded research
The National Institutes of Health (NIH) has released a Request for Information (RFI; NOT-OD-26-118) seeking input on ways to reduce administrative burden associated with NIH-funded research. The RFI invites recommendations across the full lifecycle of NIH research awards, including application requirements, pre- and post-award processes, reporting, certifications, and prior approvals. NIH is particularly interested in opportunities to streamline duplicative documentation, standardize requirements across funding programs, improve technology and data sharing, and reduce administrative requirements that disproportionately affect early-career investigators, smaller institutions, and organizations with limited administrative resources.
Reducing unnecessary administrative burden could allow researchers and research institutions to devote more time and resources to scientific discovery and innovation. However, streamlining requirements must also preserve appropriate oversight, research integrity, and accountability for federal funds. Accordingly, NIH is seeking specific, actionable recommendations that identify existing burdens and propose practical alternatives, including opportunities to simplify processes, improve information systems, and adopt more efficient, risk-based approaches to oversight.
Action opportunity: Researchers, research administrators, institutional officials, professional and scientific organizations, and other interested parties are encouraged to respond to the RFI through NIH’s online submission form by the December 8 deadline.
Provide feedback on the DOD Alzheimer’s Research Program
The Department of Defense (DOD) has posted a request for information (RFI) to solicit feedback on their Alzheimer’s Research Program (AZRP). The structured RFI is intended to help shape the future research direction of the AZRP, a Congressionally Directed Medical Research Program (CDMRP) aimed at funding impactful, solution-oriented research to address critical needs and improve quality of life for service members, veterans, their families, and the public who are living with Alzheimer’s disease and related disorders.
Appropriations for the AZRP from Fiscal Years (FY) 2011 – 2026 totaled $228 million. As of October 2026, FY2027 funds for the AZRP have not been appropriated. Responses to the RFI survey questions (also available for download here) will help support strategic program planning for FY2027 and beyond. The DOD invites feedback from all stakeholders, including academia, industry, community and non-profit organizations, scientific groups, federal agencies, and the public.
Action opportunity: Interested parties are encouraged to respond to the RFI by completing the survey by the December 4 deadline.
Provide comment on CMS proposed rule amending regulations for the Medicare Advantage and Part D programs
The Centers for Medicare and Medicaid Services (CMS) has released a proposed rule (CMS-4214-P) that amends the regulations for the Medicare Advantage (MA) program and the Medicare Prescription Drug Benefit (Part D) program to implement key sections of the Consolidated Appropriations Act of 2026 (CAA), including:
- Section 6219: Reducing the generic drug copayment from $1 to $0 for full-benefit dual-eligible individuals at or below 100% of the Federal Poverty Level, starting Jan. 1, 2028. CMS estimates this proposed change would affect approximately six million beneficiaries.
- Section 6220: Codifying regulations to implement the Requiring Enhanced and Accurate Lists of (REAL) Health Providers Act, which establishes new provider directory verification and accuracy requirements for MA organizations beginning in contract year 2028. MA plans would be required to verify and update their provider directory information at least every 90 days and report an accuracy score to CMS. Plans would also prominently display these scores on their public-facing directories, empowering beneficiaries to choose plans with confidence. CMS also proposes codifying the statutory requirements for contract year 2029, including requiring CMS to publicly display provider directory accuracy scores in a machine-readable format and MA organizations to prominently display those scores in their provider directories.
- Section 6224: Proposals to add new requirements governing the remuneration that pharmacy benefit managers (PBMs) and their affiliates may receive for services in connection with the utilization of Part D drugs, data reporting by PBMs to Part D prescription drug plan (PDP) sponsors and CMS, and other requirements.
Proposed changes under CMS-4214-P have the potential to improve affordability, access to qualified healthcare providers, and prescription drug transparency for people living with Alzheimer’s disease and related disorders, their care partners, and families..
Action opportunity: Interested parties are encouraged to submit commits on the docket by the December 15 deadline.
Respond to the Senate Finance Committee RFI on long-term care policy proposals
The Senate Finance Committee’s Ranking Member Senator Ron Wyden (D-OR) has released a Request for Information (RFI) seeking input on a range of policy proposals aimed at improving long-term care for all Americans. The RFI seeks feedback across three general areas:
- Making home care more affordable and accessible
- Improving nursing home quality
- Strengthening the long-term care workforce
These three issues are especially important for the Alzheimer’s disease and related disorders (AD/ADRD) community. People living with AD/ADRD require a workforce with specialized training and support, yet dementia-capable care remains unevenly available — the high costs of home- and community-based services (HCBS) and long-term services and supports (LTSS) create significant affordability challenges for families. Furthermore, current immigration policies are exacerbating an already severe workforce shortage, with especially profound consequences for AD/ADRD families who often face years of intensive care needs and the cumulative physical, mental health, and financial toll of caregiving.
Comments received via the RFI will help shape future legislation guided by five principles: universal access, simplicity, flexibility, workforce investments, and safeguards against abuse and waste.
Action opportunity: Interested parties are encouraged to review the RFI and consider submitting comments to homecare@finance.senate.gov by the December 18 deadline.
Apply to the NIH INCLUDE Voices: Research in Action Challenge
The National Institutes of Health (NIH) is accepting submissions for the INCLUDE Voices: Research in Action Challenge. Part of the NIH’s INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project, the Challenge invites people with Down syndrome, families, caregivers, researchers, clinicians, students, advocacy organizations, and other members of the Down syndrome community to create original content that sparks conversations about the future of Down syndrome research, highlights how research is improving lives, and encourages greater participation in research. The Challenge offers a total prize purse of $50,000.
Action opportunity: Interested parties are encouraged to apply, following Challenge submission guidance, by the December 18 deadline.
Respond to the NIH RFI on standardized common data elements for menopause research
The National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) has issued a Request for Information (RFI; NOT-OD-26-111) seeking input on developing standardized Common Data Elements (CDEs) for menopause research and clinical care. These standardized questions and response options are intended to improve consistency, interoperability, and data sharing across research studies, clinical settings, and health systems.
The RFI requests feedback across six overarching areas:
- Priority Domains and Concepts
- Data Tiering
- Alignment With Existing Standards
- Population Considerations
- Implementation and Burden
- Engagement of Key Interested Parties
Women are disproportionately affected by Alzheimer’s disease, and emerging research suggests that the menopausal transition may influence brain health and cognitive aging. Developing standardized CDEs will aid in capturing menopause-related data consistently and advancing research on sex differences in Alzheimer’s disease and related disorders.
Action opportunity: Researchers, health care providers, professional organizations, patient advocacy groups, data standards experts, and other interested parties are encouraged to submit feedback through the NIH RFI portal by the December 18 deadline.
Provide comment on NIH’s proposed data and safety monitoring policy updates
The National Institutes of Health (NIH) has issued a Request for Information (RFI; NOT-OD-27-006) seeking public input on proposed updates to its Policy for Data and Safety Monitoring. The proposed policy updates would expand data and safety monitoring requirements beyond clinical trials to encompass all NIH-supported clinical research, including observational, epidemiological, behavioral, and health services research. The updated approach emphasizes risk-based monitoring, with oversight proportional to each study’s potential risks to participant safety and well-being and the quality and integrity of research data. NIH also proposes requiring NIH Institutes, Centers, and Offices to review and approve study-specific monitoring plans, while allowing greater flexibility in monitoring approaches, including removing the blanket requirement for Data and Safety Monitoring Boards for all Phase 3 and multisite clinical trials. NIH is seeking feedback on whether the proposed policy appropriately strengthens research oversight, areas where additional guidance or clarification may be needed, and supplemental resources, tools, templates, and model monitoring plans that could support implementation while minimizing administrative burden.
Action opportunity: Interested parties are encouraged to provide input via the comment form by the January 6 deadline.
Submit comments on CMS proposed rule on Medicare- and Medicaid-participating providers and suppliers
The Centers for Medicare and Medicaid Services (CMS) has released a proposed rule (CMS-3484-P), “Cutting Administrative Requirements for Excellence in Patient Care (CARE),” which recommends regulatory revisions to the Conditions of Participation (CoPs), Conditions for Coverage (CfCs), and Requirements for Participation for Medicare- and Medicaid-participating providers and suppliers (collectively referred to as CoPs). The agency also proposes rescinding certain Medicaid institutional payment transparency reporting requirements to reduce the burden for states and institutional providers. CMS conducted a comprehensive review of the CoPs for all 21 provider and supplier types, as well as some payment policies, to identify opportunities to reduce administrative burden while maintaining patient safety and quality care. According to CMS, the agency identified obsolete, outdated, and excessively burdensome regulations that it proposes to eliminate or reform to enhance the effectiveness of facility operations and reduce unnecessary burden or other costs, with a particular focus on freeing up resources that health care providers could otherwise use to improve patient health and safety.
Of particular concern for the Alzheimer’s disease and related disorders community, CMS’s proposed rule would remove the requirement for the active involvement of representatives of direct care staff in conducting a long-term care (LTC) facility assessment and remove the requirement for LTC facilities to provide Ombudsman notice of resident transfers related to emergent care. CMS is including comment solicitations in this proposed rule to obtain input from interested parties related to the following topics:
- Allowing LTC facility residents to opt-out of having a discharge notice sent to the state ombudsman office.
- Strategies to minimize burden for hospitals and CAHs to comply with ongoing respiratory illness and PHE infectious illness data reporting requirements.
- Approaches to allow flexibility for providers regarding the requirement for physician supervision of certified registered nurse anesthetists (CRNAs).
- Expanding the scope of practice of physician assistants and nurse practitioners providing care in LTC facilities, especially as it pertains to performing visits currently required by a physician.
- Future policies to address Medicaid institutional workforce shortages and strengthen the institutional workforce.
Action opportunity: Interested parties are encouraged to submit comments on the docket by the January 11 deadline.
Respond to FDA RFI on patient-level data for real-world data and evidence submissions
The U.S. Food and Drug Administration (FDA) has issued a Request for Information (RFI; FDA-2026-N-10742) seeking stakeholder input on challenges and potential solutions related to submitting patient-level data from real-world data (RWD) analyses included in drug and biologic product marketing applications. The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) are seeking perspectives on barriers involving data ownership, privacy requirements, including Health Insurance Portability and Accountability Act (HIPAA) and General Data Protection Regulation (GDPR), and data-use agreements.
Specifically, the FDA seeks input on challenges with:
- Challenges with patient-level data submission
- Potential solutions for data-use agreements that enable more efficient RWD sharing with FDA
- Solutions which allow FDA to receive, review, and retain patient level data from external parties
- How FDA might collaborate with external partners to address these challenges
Responses will inform FDA’s strategic planning, policy development, and information technology modernization efforts.
Action opportunity: Interested parties are encouraged to submit comments on the docket by January 11.
Encourage support for AD/ADRD-relevant legislation
There are several pieces of legislation relevant to the Alzheimer’s disease and Alzheimer’s disease-related disorders (AD/ADRD) community. The bills being tracked by the LEAD Coalition are listed on our Our Activities page and real-time action updates are available via the legislative tracking spreadsheet. We especially want to call attention to the ASAP Act (H.R.6130/ S.3267) and CHANGE Act (H.R.3501 / S.1799), for which the Coalition has submitted letters of support (ASAP; CHANGE).
Action opportunity: We encourage all LEAD Coalition members and allies to track and support these pieces of legislation. If relevant legislation is missing from our list, we encourage individuals to share bills with the LEAD Coalition’s Federal Policy Director, Courtney Wallin (cwallin@leadcoalition.org), for review and consideration.
